Conditions: Beta-thalassemia Iron Overload
Keywords: Iron Chelation Deferasirox Chelator Desferal beta-thalassemia Iron overload
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 30
Healthy volunteers: no

Brief summary:
The purpose of this trial is to evaluate changes in cardiac iron as measured by MRI T2\* in beta-thalassemia patients with deferasirox treatment.

Detailed description:

Arms:
arm 1: Participants received Deferasirox 30 milligrams per kilogram per day (mg/kg/day) orally once daily (OD), 30 minutes before breakfast, preferably around the same time every morning if possible. Deferasirox tablets were dropped into water or orange juice, or apple juice and stirred until completely dispersed. For doses less than 1 gram (g), tablets were dissolved in at least 100 milliliter (mL) of liquid; for doses of 1 to 3 g, tablets were dissolved in at least 200 mL. After tablets were fully disintegrated, the liquid was promptly consumed.

Interventions: intervention 1: Deferasirox
Intervention descriptions: intervention 1: Oral deferasirox 30mg/kg/day once per day for 77 weeks.

Protocol document: